Diabetic retinopathy is an abnormality of the microvasculature of the retina that occurs to almost all patients with chronic diabetes mellitus.
It is one of the leading cause of blindness worldwide and principal cause of impaired vision in patients aged 25-75 years of age.
The abnormality causes microaneurysms, retinal hemorrhages, lipid exudates, macular edema & neovascular vessel growth that may lead to blindness.
Unintentional treatment interruptions in diabetic retinopathy patients, especially those with proliferative disease, managed with antivascular endothelial growth factor (anti-VEGF) therapy alone can result in irreversible blindness, as shown in a recent study.
Diabetic retinopathy is a leading cause of blindness, making early detection of this condition crucial. Dr Yong Shao Onn from the Eagle Eye Centre at Mt Alvernia Hospital, Singapore, speaks to Roshini Claire Anthony on the diagnosis and treatment options.
Intra-individual variability in serum creatinine levels and estimated glomerular filtration rate (eGFR) over 3 years was independently associated with the presence as well as the severity of diabetic retinopathy (DR) in patients with type 2 diabetes (T2D), indicating that variability in these biomarkers can serve as predictors to identify T2D patients at risk of DR, suggests a local study.
In the treatment of proliferative diabetic retinopathy (DR), eyes gain vision and rarely develop vision-impairing central-involved diabetic macula oedema (DME) over 2 years with ranibizumab, according to a posthoc analysis. In contrast, factors such as poor glycaemic control and more severe DR increase the likelihood of losing visual acuity and developing DME following panretinal photocoagulation (PRP).
Administering intravitreal injections of ranibizumab in addition to panretinal photocoagulation (PRP) appears to be more effective than PRP monotherapy in terms of neovascularization regression in patients with high-risk proliferative diabetic retinopathy, according to a study.
Individuals who have a higher perception of barriers to diabetes self-management may be at an elevated risk for diabetic retinopathy (DR), according to findings of the Singapore Diabetes Management Project study.
Individuals with diabetic retinopathy (DR) appear to have thicker macula and outer retina compared with those who do not have the diabetic eye disease, and such thickening is more pronounced in eyes with severe DR, according to a study.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.